EP0472659A4 - T-lymphotropic retrovirus monoclonal antibodies - Google Patents
T-lymphotropic retrovirus monoclonal antibodiesInfo
- Publication number
- EP0472659A4 EP0472659A4 EP19900909217 EP90909217A EP0472659A4 EP 0472659 A4 EP0472659 A4 EP 0472659A4 EP 19900909217 EP19900909217 EP 19900909217 EP 90909217 A EP90909217 A EP 90909217A EP 0472659 A4 EP0472659 A4 EP 0472659A4
- Authority
- EP
- European Patent Office
- Prior art keywords
- hiv
- amino acid
- antibodies
- antigen
- antibody
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Ceased
Links
- 241001430294 unidentified retrovirus Species 0.000 title description 6
- 208000031886 HIV Infections Diseases 0.000 claims abstract description 52
- 241000713340 Human immunodeficiency virus 2 Species 0.000 claims abstract description 51
- 238000001514 detection method Methods 0.000 claims abstract description 21
- 239000000427 antigen Substances 0.000 claims description 33
- 102000036639 antigens Human genes 0.000 claims description 33
- 108091007433 antigens Proteins 0.000 claims description 33
- 238000000034 method Methods 0.000 claims description 17
- 125000003275 alpha amino acid group Chemical group 0.000 claims description 15
- 238000009007 Diagnostic Kit Methods 0.000 claims description 12
- 150000001413 amino acids Chemical class 0.000 claims description 9
- 125000000539 amino acid group Chemical group 0.000 claims description 8
- 230000015572 biosynthetic process Effects 0.000 claims description 8
- 230000008827 biological function Effects 0.000 claims 4
- 238000002965 ELISA Methods 0.000 abstract description 23
- 108090000765 processed proteins & peptides Proteins 0.000 abstract description 21
- 102000004196 processed proteins & peptides Human genes 0.000 abstract description 19
- 238000003556 assay Methods 0.000 abstract description 18
- 241000713772 Human immunodeficiency virus 1 Species 0.000 abstract description 17
- 108090000623 proteins and genes Proteins 0.000 abstract description 15
- 102100023321 Ceruloplasmin Human genes 0.000 abstract description 4
- 108090000565 Capsid Proteins Proteins 0.000 abstract description 3
- 101710205625 Capsid protein p24 Proteins 0.000 description 22
- 101710177166 Phosphoprotein Proteins 0.000 description 22
- 101710149279 Small delta antigen Proteins 0.000 description 22
- 102100031987 Transmembrane emp24 domain-containing protein 2 Human genes 0.000 description 22
- 101710072850 Poxin Proteins 0.000 description 14
- 101710142282 Protein P26 Proteins 0.000 description 14
- 102100032106 Transmembrane emp24 domain-containing protein 3 Human genes 0.000 description 14
- 102000004169 proteins and genes Human genes 0.000 description 12
- 230000036436 anti-hiv Effects 0.000 description 8
- 239000006166 lysate Substances 0.000 description 7
- 239000013641 positive control Substances 0.000 description 7
- 230000035945 sensitivity Effects 0.000 description 6
- 238000001262 western blot Methods 0.000 description 6
- 210000004027 cell Anatomy 0.000 description 5
- 238000003119 immunoblot Methods 0.000 description 5
- 239000013612 plasmid Substances 0.000 description 5
- 230000009257 reactivity Effects 0.000 description 5
- 208000030507 AIDS Diseases 0.000 description 4
- 241000725303 Human immunodeficiency virus Species 0.000 description 4
- 241000700605 Viruses Species 0.000 description 4
- 239000013642 negative control Substances 0.000 description 4
- 239000000523 sample Substances 0.000 description 4
- 238000012216 screening Methods 0.000 description 4
- 101710177291 Gag polyprotein Proteins 0.000 description 3
- 101710125418 Major capsid protein Proteins 0.000 description 3
- 241000699666 Mus <mouse, genus> Species 0.000 description 3
- 238000002835 absorbance Methods 0.000 description 3
- 238000004458 analytical method Methods 0.000 description 3
- 230000008901 benefit Effects 0.000 description 3
- 239000003153 chemical reaction reagent Substances 0.000 description 3
- 230000009260 cross reactivity Effects 0.000 description 3
- 239000012228 culture supernatant Substances 0.000 description 3
- 238000010586 diagram Methods 0.000 description 3
- 239000002243 precursor Substances 0.000 description 3
- 239000000047 product Substances 0.000 description 3
- 238000002976 reverse transcriptase assay Methods 0.000 description 3
- 210000002966 serum Anatomy 0.000 description 3
- 239000007790 solid phase Substances 0.000 description 3
- 241000283707 Capra Species 0.000 description 2
- 101100440992 Drosophila melanogaster Crag gene Proteins 0.000 description 2
- 102000004190 Enzymes Human genes 0.000 description 2
- 108090000790 Enzymes Proteins 0.000 description 2
- 241000588724 Escherichia coli Species 0.000 description 2
- 239000000020 Nitrocellulose Substances 0.000 description 2
- 108010015780 Viral Core Proteins Proteins 0.000 description 2
- 210000004369 blood Anatomy 0.000 description 2
- 239000008280 blood Substances 0.000 description 2
- 231100000673 dose–response relationship Toxicity 0.000 description 2
- 230000004927 fusion Effects 0.000 description 2
- 238000000338 in vitro Methods 0.000 description 2
- 238000013507 mapping Methods 0.000 description 2
- 239000000203 mixture Substances 0.000 description 2
- 238000006386 neutralization reaction Methods 0.000 description 2
- 229920001220 nitrocellulos Polymers 0.000 description 2
- 238000002360 preparation method Methods 0.000 description 2
- 230000001177 retroviral effect Effects 0.000 description 2
- 238000005406 washing Methods 0.000 description 2
- HRPVXLWXLXDGHG-UHFFFAOYSA-N Acrylamide Chemical compound NC(=O)C=C HRPVXLWXLXDGHG-UHFFFAOYSA-N 0.000 description 1
- 208000031504 Asymptomatic Infections Diseases 0.000 description 1
- 238000011725 BALB/c mouse Methods 0.000 description 1
- 238000012286 ELISA Assay Methods 0.000 description 1
- SXRSQZLOMIGNAQ-UHFFFAOYSA-N Glutaraldehyde Chemical compound O=CCCCC=O SXRSQZLOMIGNAQ-UHFFFAOYSA-N 0.000 description 1
- 208000037357 HIV infectious disease Diseases 0.000 description 1
- 101710121996 Hexon protein p72 Proteins 0.000 description 1
- 108010001336 Horseradish Peroxidase Proteins 0.000 description 1
- 102100034343 Integrase Human genes 0.000 description 1
- 241000713666 Lentivirus Species 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 241001529936 Murinae Species 0.000 description 1
- 241000699670 Mus sp. Species 0.000 description 1
- 208000012902 Nervous system disease Diseases 0.000 description 1
- 108091028043 Nucleic acid sequence Proteins 0.000 description 1
- 108091034117 Oligonucleotide Proteins 0.000 description 1
- 102000015636 Oligopeptides Human genes 0.000 description 1
- 108010038807 Oligopeptides Proteins 0.000 description 1
- 206010035226 Plasma cell myeloma Diseases 0.000 description 1
- 241000276498 Pollachius virens Species 0.000 description 1
- 229920002535 Polyethylene Glycol 1500 Polymers 0.000 description 1
- 108010092799 RNA-directed DNA polymerase Proteins 0.000 description 1
- 108020004511 Recombinant DNA Proteins 0.000 description 1
- 238000012300 Sequence Analysis Methods 0.000 description 1
- 108020005202 Viral DNA Proteins 0.000 description 1
- 108010087302 Viral Structural Proteins Proteins 0.000 description 1
- JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 description 1
- 239000002671 adjuvant Substances 0.000 description 1
- 230000000890 antigenic effect Effects 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- 239000010836 blood and blood product Substances 0.000 description 1
- 229940125691 blood product Drugs 0.000 description 1
- 150000001718 carbodiimides Chemical class 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 238000012512 characterization method Methods 0.000 description 1
- 239000007795 chemical reaction product Substances 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 239000002299 complementary DNA Substances 0.000 description 1
- 239000003599 detergent Substances 0.000 description 1
- 238000003745 diagnosis Methods 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 150000002148 esters Chemical class 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 239000013604 expression vector Substances 0.000 description 1
- 239000012634 fragment Substances 0.000 description 1
- 208000033519 human immunodeficiency virus infectious disease Diseases 0.000 description 1
- 210000000987 immune system Anatomy 0.000 description 1
- 238000003018 immunoassay Methods 0.000 description 1
- 230000000984 immunochemical effect Effects 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 230000004807 localization Effects 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- MYWUZJCMWCOHBA-VIFPVBQESA-N methamphetamine Chemical compound CN[C@@H](C)CC1=CC=CC=C1 MYWUZJCMWCOHBA-VIFPVBQESA-N 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 201000000050 myeloid neoplasm Diseases 0.000 description 1
- 150000007523 nucleic acids Chemical group 0.000 description 1
- 239000002773 nucleotide Substances 0.000 description 1
- 125000003729 nucleotide group Chemical group 0.000 description 1
- 238000003752 polymerase chain reaction Methods 0.000 description 1
- 238000003908 quality control method Methods 0.000 description 1
- 238000010814 radioimmunoprecipitation assay Methods 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 239000012925 reference material Substances 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 238000012552 review Methods 0.000 description 1
- 238000012163 sequencing technique Methods 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 210000004989 spleen cell Anatomy 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- 229960000814 tetanus toxoid Drugs 0.000 description 1
- VUYXVWGKCKTUMF-UHFFFAOYSA-N tetratriacontaethylene glycol monomethyl ether Chemical compound COCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCO VUYXVWGKCKTUMF-UHFFFAOYSA-N 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 230000010415 tropism Effects 0.000 description 1
- 241001515965 unidentified phage Species 0.000 description 1
- 229960005486 vaccine Drugs 0.000 description 1
- 239000013598 vector Substances 0.000 description 1
- 230000003612 virological effect Effects 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/08—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses
- C07K16/10—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses from RNA viruses
- C07K16/1036—Retroviridae, e.g. leukemia viruses
- C07K16/1045—Lentiviridae, e.g. HIV, FIV, SIV
- C07K16/1054—Lentiviridae, e.g. HIV, FIV, SIV gag-pol, e.g. p17, p24
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2740/00—Reverse transcribing RNA viruses
- C12N2740/00011—Details
- C12N2740/10011—Retroviridae
- C12N2740/16011—Human Immunodeficiency Virus, HIV
- C12N2740/16211—Human Immunodeficiency Virus, HIV concerning HIV gagpol
- C12N2740/16222—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
Definitions
- the invention relates to monoclonal antibodies, peptides that comprise the epitopes of said monoclonal antibodies and assays utilizing said monoclonal antibodies and said peptides for the detection of T- lymphotropic retroviruses, particularly HIV-1, HIV-2 and SIV.
- the T-lymphotropic retrovirus family includes among other lentiviruses the simian retrovirus SIV and the human retroviruses HIV-1 (the likely etiologic agent of AIDS) and HIV-2. Although HIV-1 and HIV-2 are related evolutionally, nucleic acid sequence analysis reveals that HIV-2 is more closely related to SIV than it is to HIV-1. Guyader et al. (1987) noted only 42% overall genomi ⁇ sequence identity between the HIV-1 and HIV-2 isolates they compared.
- HIV-1 and HIV-2 genomes have a typical retroviral configuration comprising LTR's, ⁇ a ⁇ and env regions that encode viral structural proteins, sequences encoding one or more enzyme, including a reverse transcriptase and other ORF's and regulatory elements.
- the a ⁇ region of HIV-1 encodes a precursor peptide known as p55.
- p55 is processed to produce among other proteins the major core or capsid protein known as p24.
- the analogous crag precursor is larger, known as p57, and the major core protein is known as p26.
- Guyader et al. (1987) found only 58% identity of amino acids between HIV-1 and HIV-2 crag proteins.
- -_ Even among distant isolates of HIV-1 there is a greater than 90% identity of gag proteins. That and other data support the hypothesis that although HIV-1 and HIV-2 are somewhat related, they are nevertheless distinct retroviral species.
- HIV-1 and possibly HIV-2 have such an impact on the human immune system, it is desirable, in fact imperative that sensitive, rapid diagnostic assays for detecting presence of HIV be available for population screening, quality control in blood banks, diagnosis, furtherance of our understanding of those viruses to assure the goal of obtaining a vaccine and cure, and the like. Because of ease and convenience, it is preferable that the assays be immunology-based, such as ELISA's, and for reproducibility, specificity and consistency that the reagents be monoclonal antibodies and defined antigenic peptides.
- p24 antigenemia has been shown to be an early sign of HIV infection (Kessler et al., 1987; Wall et al., 1987) and the observation that clinical progression of AIDS sequelae is associated with reduction in anti-p24 while patients with AIDS can die with high levels of anti-env titers (Coates et al., 1987), it would be advantageous for the assay to be directed to detecting gag products such as p24/p26.
- Minassian et al. described a monoclonal antibody identified as R1C7 that was raised against HIV-2.
- R1C7 an anti-capsid antibody (p26) , reacted not only with the three HIV-2 isolates tested, but with the five HIV-l ' isolates and seven SIV isolates that were tested.
- p26 an anti-capsid antibody
- R1C7 bound to 55KD and 26KD HIV-2 proteins, to 24KD and 55KD HIV-l proteins and to a 28KD SIV protein.
- Niedrig et al. developed a panel of 29 monoclonal antibodies to HIV-l.
- One antibody was directed to pl7 and its precursor p32 whereas the remainder reacted with p24 and some of those also reacted with p55.
- the pl7 antibody was found to be HIV-l specific.
- 20 reacted in immunoblots with the corresponding capsid protein (p 6) of HIV-2 and five of those also recognized the corresponding SIV protein, p28.
- Niedrig et al. make no mention of antibody titer, the efficacy of the antibodies in a antigen capture assay or which of the antibodies bind to p26, p55 or both.
- several of antibodies reacted with a 22KD protein of unknown function in HIV-2 preparations.
- the assays use a variety of techniques such as Western blot, enzyme- linked immunosorbent assay (ELISA) or indirect immuno- fluorescent assay and employ either antibodies to whole virus or purified viral antigens, see for example, Gallo et al., U.S. Patent No. 4,520,113; Sarngadharan, et al., (1984); and Robert-Guroff et al. (1982).
- ELISA enzyme- linked immunosorbent assay
- indirect immuno- fluorescent assay employ either antibodies to whole virus or purified viral antigens, see for example, Gallo et al., U.S. Patent No. 4,520,113; Sarngadharan, et al., (1984); and Robert-Guroff et al. (1982).
- the instant invention relates to monoclonal antibodies, the cell lines producing those antibodies, the peptides that comprise the epitopes of those antibodies and assays using those antibodies and peptides for the detection of HIV-l and HIV-2 gene products as well as SIV gene products.
- the antibodies react with the p24/p26 capsid protein.
- the nonapeptide that comprises an HIV-l/HIV-2 conserved epitope is disclosed and a capture ELISA using a combination of three monoclonal antibodies that can detect simultaneously HIV-l and HIV-2 is disclosed.
- Figure 1 Graph depicting reactivity of culture supernatants in capture ELISA. A detailed legend appears in Table 1.
- FIG. 1 Protein A-purified antibodies were used as probe to separated HIV-2 proteins in immunoblots. Lanes 1 and 2 are positive controls and Lane 3 is a negative control.
- Figure 4 Diagram of some of the recombinant p24 peptides used to map epitopes.
- Figure 5 Diagram of four regions of p24 to which various monoclonal antibodies bind.
- FIG. 6 Photographs of Westerns reacting various monoclonals with blotted gag and gag fragments. Lane 1 in each photo contains whole virus lysate. Lane 5 in each photo is a negative control p24 " plasmid and Lane 6 in each photo is another negative control containing non-HIV-infected MOLT lysate. Figure 7. Graph representing results of ELISA's using sequential overlapping nonapeptides as antigen to determine epitope of 7-D4.
- Figure 8 Diagram depicting epitope mapping using sequential overlapping nonapeptides as antigen in ELISA.
- Figure 9 Composition of the regions that comprise the 7-D4 epitope.
- FIG. 10 Graph of sensitivity of a capture ELISA using two anti-p24 antibodies, 6-C10 and 5-B4, on the solid phase and HIV-l infected MOLT 3 lysate as the antigen.
- An HRP conjugated human anti-HIV was the reporter.
- Figure 11 Graph of sensitivity of a capture ELISA using 6-C10 and 5-B4 with and without 7-D4 on the solid phase to detect p26 of HIV-2.
- Figure 13 Comparison of HIV-l dose response curves between the three antibody capture ELISA and a reverse transcriptase assay.
- the instant invention relates to monoclonal antibodies and their production, im unoassays and oligopeptides.
- the methods that were used are known in the art and are discussed only briefly throughout the specification. Suitable methods to practice the invention may be found in Meth Enzymology 121 r (1986) and other available reference materials.
- Monoclonal antibodies were produced according to established procedures (Kohler & Milstein, 1975) .
- mice Female BALB/c mice were immunized intraperitoneally repeatedly with lysates of HIV-l infected MOLT 3 cells emulsified in complete Freund's adjuvant (50%) . Sensitized spleen cells were fused with P3X63-Ag8.653 myeloma cells using PEG 1500. Heterokaryons were selected in HAT medium, cloned and screened for reactivity to HIV antigens in a capture ELISA. The IgG fraction of polyclonal human anti-HIV was coated onto wells of icrotiter dishes. HIV-l (produced in MOLT 3 cells) and culture supernatants were added simultaneously to the wells. Bound murine antibodies were detected with an enzyme-labelled anti- mouse Ig antibody. Data representative of the screening is depicted in Figure 1. Designation of the sample numbers is set forth in Table 1.
- Candidate anti-HIV clones were tested further in Western blots (Towbin et al., 1979). Lysates of HIV- infected MOLT 3 cells were separated through a 12% acrylamide gel under denaturing conditions. The proteins were transferred to nitrocellulose and individual strips were blocked and reacted with the culture supernatants. Bound antibody was detected using an enzyme-labelled goat anti-mouse Ig antibody. Antibodies reacting specifically with p24 were selected ( Figure 2) . Designation of the strips is set forth in Table 2. Table 2
- 7-D4 recognized a protein of approximately 27,000 molecular weight in lysates of SIV ⁇ c, Epitooe Mapping
- the amino acids that comprise the p24 epitope of 7- D4 were mapped in the following manner.
- the gag region and portions of gag were subcloned in an expression vector. Briefly, viral DNA of a bacteriophage (cDNA library HIV-l ⁇ ., clone HAT 3 (Starcich et al., (1986)) was digested with EcoRI and by ligation into the pBR322- derived plasmid pMLB1113 to produce a plasmid identified as clone 29 which contained the EcoRI/SstI gag/pol ORF. Clone 29 was digested with SstI to remove extraneous vector sequences and religated to produce plasmid gag/pol 1.2.
- This latter plasmid was sonicated, blunt- ended and ligated with EcoRI linkers. The mixture was then digested with EcoRI. ligated into AORF8 (Meissner et al. 1987) and packaged.
- a AORF8 expression library was generated in E. coli and screened with a human anti- HIV polyclonal antibody and a mouse anti-p24 (HIV-l) monoclonal antibody. The positives were selected, expanded and the expressed peptides were characterized by Western blotting, immunoassay and nucleotide sequencing. The recombinant p24 peptides gag 8, gag 126, gag 107 and gag 141 were expressed in E. coli.
- clone 29 was used as a template and oligonucleotides corresponding to the 5" and 3' ends of the published sequence were used in a polymerase chain reaction to generate a complete sequence of the gag protein p24.
- the 5' end contained an EcoRI site and the 3• end contained a IJamHI site.
- the reaction product was digested with EcoRI and B_amHI and then ligated into PMLB1113.
- the characterization of the recombinant p24 peptides is presented in Figure 4.
- the various recombinant p24 peptides were used as antigen in ELISA's and in Western blots to determine whether or not a given monoclonal antibody bound a given peptide.
- the reactivity pattern of any one monoclonal antibody with the panel of p24 peptides allowed a localization of the recognized epitope to one of four regions as shown in Table 4 and Figures 5 and 6.
- Synthetic peptides are configured after the epitope sequence and either unmodified or conjugated to carriers are used as antigen.
- peptides can be conjugated to PPD, tetanus toxoid, KLH or BSA using glutaraldehyde, carbodiimide or N-maleimidobenzoyl hydroxuccinimide ester.
- Antibodies may be raised n vivo as in mice, goats or other lab animals or in vitro using a system of materials and methods similar to the IVIS of Hana Biologies (Alameda, CA) .
- Another benefit is that large quantities of the epitope sequence can be produced synthetically or using standard recombinant DNA techniques as described above and the peptides can serve as antigen in immunology-based assays and kits for the detection of circulating antibody or for the detection of circulating antigen in an inhibition type assay.
- Another benefit relates to improving the assays disclosed herein. Without extending the survey, it is unclear whether the epitope identified in the HIV-l isolate described herein is specific to that isolate and furthermore to the HIV-2 and SIV isolates described herein.
- the epitope can be engineered, that is substituting one or more amino acids or alternatively derivitizing the epitope, etc., with a view to identifying a related sequence with a greater degree of conservation among a larger variety of HIV isolates or to obtaining a related sequence with a greater degree of reactivity in assays.
- the nonapeptide analysis apparently identified a discrete linear epitope comprised of amino acids 142- 158 of the HIV-l gag that is conserved in HIV-2 and SIV, it is to be understood that the instant invention relates to monoclonal antibodies, epitopes of said monoclonal antibodies and assays using said antibodies and said peptides that are capable of detecting gag encoded proteins of HIV-l, HIV-2 and SIV.
- each was used as a capture or HRP- conjugate antibody in a sandwich assay. Briefly, the monoclonal antibody was coated on wells and 10 ⁇ l of disruption buffer added. The antigen samples suspended in detergent buffer or controls in a volume of 100 ⁇ l were added next and incubated at 37 ⁇ C for 90 minutes.
- Antibodies 5-B4, 6-C10 and 7-E10 worked best as both capture and conjugated antibodies. Maximal signals were obtained with the HRP-human anti-HIV as the conjugate.
- the sensitivity of the capture ELISA using these three antibodies is less than 10 pg/ml (less than 1 pg/well) of HIV-l p24 antigen and less than 0.5 ng/ml of HIV-2 p26 antigen ( Figure 12) .
- the sensitivity is found despite the presence of HIV antibodies in the
- a capture ELISA using the three antibodies 5-B4, 6-C10 and 7-D4 was also compared to a reverse transcriptase assay for the detection of whole virus.
- the ELISA was 25,000 times more sensitive than the reverse transcriptase assay ( Figure 13) .
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Virology (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- General Health & Medical Sciences (AREA)
- Genetics & Genomics (AREA)
- Medicinal Chemistry (AREA)
- Biophysics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Gastroenterology & Hepatology (AREA)
- AIDS & HIV (AREA)
- Hematology (AREA)
- Oncology (AREA)
- Immunology (AREA)
- Peptides Or Proteins (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
Abstract
Description
Claims
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US35188289A | 1989-05-15 | 1989-05-15 | |
US351882 | 1989-05-15 |
Publications (2)
Publication Number | Publication Date |
---|---|
EP0472659A1 EP0472659A1 (en) | 1992-03-04 |
EP0472659A4 true EP0472659A4 (en) | 1992-04-08 |
Family
ID=23382831
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EP19900909217 Ceased EP0472659A4 (en) | 1989-05-15 | 1990-05-14 | T-lymphotropic retrovirus monoclonal antibodies |
Country Status (8)
Country | Link |
---|---|
EP (1) | EP0472659A4 (en) |
JP (1) | JPH04505621A (en) |
KR (1) | KR0168447B1 (en) |
AU (1) | AU642886B2 (en) |
CA (1) | CA2032509A1 (en) |
FI (1) | FI915333A0 (en) |
WO (1) | WO1990014358A1 (en) |
ZA (1) | ZA903492B (en) |
Families Citing this family (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DK53291D0 (en) * | 1991-03-25 | 1991-03-25 | Carlbiotech Ltd As | SMALL PEPTIDES AND PEPTID RELATED SUBSTANCES AND PHARMACEUTICAL PREPARATIONS CONTAINING SUCH COMPOUNDS |
SE9101863D0 (en) * | 1991-06-13 | 1991-06-13 | Replico Medical Ab | PEPTIDES, DIAGNOSTIC ANTIGEN, VACCINE COMPOSITION AND PROCEDURES FOR SELECTING HIV STARMS |
JP4278174B2 (en) * | 1994-10-20 | 2009-06-10 | アンスティテュ・パストゥール | Nucleotide sequence of HIV-1 O group (or subgroup) retroviral antigen |
FR2777285B1 (en) * | 1998-04-10 | 2000-05-19 | Bio Merieux | PEPTIDE LIGAND WITH SPECIFIC AFFINITY TO HIV-1 RETROVIRUS P24 PROTEIN |
US6818392B2 (en) * | 2000-12-06 | 2004-11-16 | Abbott Laboratories | Monoclonal antibodies to human immunodeficiency virus and uses thereof |
Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0345461A2 (en) * | 1988-06-10 | 1989-12-13 | Abbott Laboratories | Mouse monoclonal antibodies to HIV-1P24 and their use in diagnostic tests |
Family Cites Families (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4755457A (en) * | 1985-02-05 | 1988-07-05 | Robert Guroff Marjorie | Method for detecting HTLV-III neutralizing antibodies in sera |
US4843011A (en) * | 1985-08-01 | 1989-06-27 | Akzo N.V. | Monoclonal antibodies for binding HTLV-III proteins, and cell lines for their production |
US4888290A (en) * | 1987-11-06 | 1989-12-19 | Coulter Corporation | Monoclonal antibody specific to HIV antigens |
EP0330359A3 (en) * | 1988-02-25 | 1991-06-05 | Bio-Rad Laboratories, Inc. | Composition useful in the diagnosis and treating of hiv-1 infection |
CA2017021A1 (en) * | 1989-05-22 | 1990-11-22 | Johannes Jacobus Schalken | Diagnostic test for detecting antibodies directed against antigens of one or more related viruses |
DE4039925A1 (en) * | 1990-12-14 | 1992-06-17 | Behringwerke Ag | SELECTED PEPTIDES OF THE GROUP-SPECIFIC ANTIGEN (GAG) OF HUMANEM IMMUNE DEFICIENCY VIRUS (HIV), THEIR PRODUCTION AND USE |
-
1990
- 1990-05-08 ZA ZA903492A patent/ZA903492B/en unknown
- 1990-05-14 JP JP2508986A patent/JPH04505621A/en active Pending
- 1990-05-14 CA CA002032509A patent/CA2032509A1/en not_active Abandoned
- 1990-05-14 WO PCT/US1990/002874 patent/WO1990014358A1/en not_active Application Discontinuation
- 1990-05-14 KR KR1019910700048A patent/KR0168447B1/en not_active IP Right Cessation
- 1990-05-14 EP EP19900909217 patent/EP0472659A4/en not_active Ceased
- 1990-05-14 AU AU58355/90A patent/AU642886B2/en not_active Ceased
-
1991
- 1991-11-12 FI FI915333A patent/FI915333A0/en unknown
Patent Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0345461A2 (en) * | 1988-06-10 | 1989-12-13 | Abbott Laboratories | Mouse monoclonal antibodies to HIV-1P24 and their use in diagnostic tests |
Non-Patent Citations (1)
Title |
---|
See also references of WO9014358A1 * |
Also Published As
Publication number | Publication date |
---|---|
EP0472659A1 (en) | 1992-03-04 |
ZA903492B (en) | 1991-02-27 |
AU642886B2 (en) | 1993-11-04 |
KR920701243A (en) | 1992-08-11 |
AU5835590A (en) | 1990-12-18 |
FI915333A0 (en) | 1991-11-12 |
CA2032509A1 (en) | 1990-11-16 |
KR0168447B1 (en) | 1999-01-15 |
WO1990014358A1 (en) | 1990-11-29 |
JPH04505621A (en) | 1992-10-01 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US6013484A (en) | HIV-3 retrovirus and its use | |
EP0201540B2 (en) | Envelope antigens of lymphadenopathy associated virus and their applications | |
Palker et al. | Mapping of immunogenic regions of human T cell leukemia virus type I (HTLV-I) gp46 and gp21 envelope glycoproteins with env-encoded synthetic peptides and a monoclonal antibody to gp46. | |
US4888290A (en) | Monoclonal antibody specific to HIV antigens | |
JP2958346B2 (en) | Anti-HIV-2 monoclonal antibody and method for detecting anti-HIV-2 gp41 antibody using the same | |
US5210181A (en) | T-lymphotropic retrovirus peptide | |
US5254457A (en) | Monoclonal antibodies and method for identifying different aids-related viruses | |
Avrameas et al. | Localisation of three epitopes of the env protein of feline immunodeficiency virus | |
AU642886B2 (en) | T-lymphotropic retrovirus monoclonal antibodies | |
Boucher et al. | Immune response and epitope mapping of a candidate HIV‐1 p17 vaccine HGP30 | |
Walther et al. | Evaluation of HIV-1/HIV-2 immunoblots for detection of HIV-2 antibodies | |
Rimmelzwaan et al. | Gag-and env-specific serum antibodies in cats after natural and experimental infection with feline immunodeficiency virus | |
Lombardi et al. | Detection of B epitopes on the p24 gag protein of feline immunodeficiency virus by monoclonal antibodies | |
van Tijn et al. | Antigenicity of Linear B-Cell Epitopes in the C1, V1, and V3 Region of HIV-1 gp120 | |
US5624795A (en) | Isolation and characterization of a novel chimpanzee lentivirus, designated simian immunodeficiency virus isolate cpz-ant | |
Kienzle et al. | Immunological study of the Nef protein from HIV-1 by polyclonal and monoclonal antibodies | |
Cogniaux et al. | Characterization of monoclonal antibodies against the p17 core protein of the human immunodeficiency virus 1 | |
Gallina et al. | Major antigenic domain recognized by monoclonal antibodies maps within the carboxy‐terminal moiety of a recombinant human immunodeficiency virus‐1 p24 protein | |
Bodéus et al. | An anti-HIV-1 gag protein rat monoclonal antibody library | |
EP1568767A2 (en) | Dna fragments of lav genes |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PUAI | Public reference made under article 153(3) epc to a published international application that has entered the european phase |
Free format text: ORIGINAL CODE: 0009012 |
|
17P | Request for examination filed |
Effective date: 19911108 |
|
AK | Designated contracting states |
Kind code of ref document: A1 Designated state(s): AT BE CH DE DK ES FR GB IT LI NL SE |
|
A4 | Supplementary search report drawn up and despatched |
Effective date: 19920218 |
|
AK | Designated contracting states |
Kind code of ref document: A4 Designated state(s): AT BE CH DE DK ES FR GB IT LI NL SE |
|
RAP1 | Party data changed (applicant data changed or rights of an application transferred) |
Owner name: BUTMAN, BRYAN T. Owner name: VENETTA, THOMAS M. Owner name: AKZO NOBEL N.V. |
|
17Q | First examination report despatched |
Effective date: 19940729 |
|
GRAG | Despatch of communication of intention to grant |
Free format text: ORIGINAL CODE: EPIDOS AGRA |
|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: THE APPLICATION HAS BEEN REFUSED |
|
18R | Application refused |
Effective date: 19990327 |